Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 9/20 | 0.41 |
| ▸ | FNTB | P49356 | 9/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30011175 | 1.00 | ACE (0.59) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL30010893 | 1.00 | ACE (0.59) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL30011166 | 1.00 | ACE (0.59) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL30931518 | 0.93 | ACE (0.51) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL30685989 | 0.91 | ACE (0.50) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL19196091 | 0.90 | ACE (0.56) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL29461589 | 0.90 | ACE (0.56) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL28101261 | 0.90 | ACE (0.47) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL28101266 | 0.90 | ACE (0.47) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL19379981 | 0.90 | ACE (0.56) | ACEKDM4EMAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345411-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-20250345410-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-12390520-B2 | Vaccination in newborns and infants | Cure Vac SE (DE) | 2025-08-19 | — | — | US | disclosed |
| US-20240390478-A1 | VACCINATION IN ELDERLY PATIENTS | CureVac SE (DE) | 2024-11-28 | — | — | US | disclosed |
| US-12036277-B2 | Vaccination with mRNA-coded antigens | CureVac SE (DE) | 2024-07-16 | — | — | US | disclosed |
| US-20240197857-A1 | VACCINATION WITH mRNA-CODED ANTIGENS | CureVac SE (DE) | 2024-06-20 | — | — | US | disclosed |
| US-11975064-B2 | Vaccination with mRNA-coded antigens | CureVac SE (DE) | 2024-05-07 | — | — | US | disclosed |
| EP-3508476-B1 | AMINO MERCAPTAN COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PROTECTION AGAINST RADIATION | SHANGHAI KECHOW PHARMA INC (CN) | 2023-11-22 | — | — | EP | disclosed |
| US-20230302146-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CureVac SE (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230285594-A1 | COMPLEXATION OF NUCLEIC ACIDS WITH DISULFIDE-CROSSLINKED CATIONIC COMPONENTS FOR TRANSFECTION AND IMMUNOSTIMULATION | CureVac SE (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230233662-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2023-07-27 | — | — | US | disclosed |
| US-11672856-B2 | Vaccination in newborns and infants | CureVac SE (DE) | 2023-06-13 | — | — | US | disclosed |
| US-11478552-B2 | Hybrid carriers for nucleic acid cargo | CUREVAC AG (DE) | 2022-10-25 | — | — | US | disclosed |
| WO-2018041245-A1 | AMINO MERCAPTAN COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PROTECTION AGAINST RADIATION | 中国医学科学院放射医学研究所 | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478552-B2 | Hybrid carriers for nucleic acid cargo | HNRNPH1, HNRNPH3, SNRPE | ACE 4699/4885KDM4E 4808/4885MAPT 3024/4885 |
| US-20250345410-A1 | VACCINATION IN NEWBORNS AND INFANTS | HLA-DRB1, TLR3, TLR9 | ACE 4227/4885KDM4E 3834/4885MAPT 3792/4885 |
| US-20230302146-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | HNRNPH1, HNRNPH3, SNRPE | ACE 4699/4885KDM4E 4808/4885MAPT 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.